Clinical Development Program
Compounds identified using the PepMetics® platform are licensed to pharmaceutical partners, who lead nonclinical and clinical development studies.
E7386
|CBP/β-Catenin | Transcription Factor/PPI | Oncology |
Hit Identification
Hit to Lead
Lead OP
Preclinical
Phase 1
Phase 2
Phase 3
About E7386
E7386 is an orally available inhibitor of the CBP/β-catenin interaction, jointly discovered by PRISM BioLab and Eisai Co., Ltd. It targets the CBP/β-catenin signaling pathway, which is implicated in cancer progression and malignancy.
Clinical studies demonstrated antitumor activity of E7386, leading to the achievement of proof of concept (POC) in November 2021. E7386 is currently being evaluated in clinical trials for solid tumors, both as a monotherapy and in combination with other anticancer agents.
PRI-724（OP-724）
|CBP/β-Catenin | Transcription Factor/PPI | Oncology |
Hit Identification
Hit to Lead
Lead OP
Preclinical
Phase 1
Phase 2
Phase 3
About PRI-724 (OP-724)
PRI-724 (generic name: Foscenvivint) is a CBP/β-catenin interaction inhibitor discovered by PRISM BioLab. Rights to the compound for non-oncology indications were out-licensed to Ohara Pharmaceutical Co., Ltd. Clinical studies in patients with HCV- and HBV-related liver cirrhosis demonstrated improvements in liver stiffness and hepatic function, resulting in the achievement of proof of concept (POC) in April 2022. Foscenvivint is currently being
evaluated in clinical trials including MASH-related liver cirrhosis too.
